Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Gross Profit (2018 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Gross Profit for 8 consecutive years, with $177.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Gross Profit rose 20.65% to $177.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $564.0 million, a 16.77% increase, with the full-year FY2025 number at $564.0 million, up 16.77% from a year prior.
  • Gross Profit was $177.9 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $131.9 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $177.9 million in Q4 2025 to a low of $73.8 million in Q1 2022.
  • A 5-year average of $105.3 million and a median of $96.1 million in 2021 define the central range for Gross Profit.
  • Peak YoY movement for Gross Profit: surged 187.16% in 2021, then dropped 21.62% in 2022.
  • Ultragenyx Pharmaceutical's Gross Profit stood at $79.9 million in 2021, then increased by 22.72% to $98.0 million in 2022, then rose by 17.62% to $115.3 million in 2023, then rose by 27.91% to $147.5 million in 2024, then increased by 20.65% to $177.9 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Gross Profit are $177.9 million (Q4 2025), $131.9 million (Q3 2025), and $143.5 million (Q2 2025).